All In Biotech

Drug Trial Radar · NCT05342792

Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

Metronomic Capecitabine With or Without Tislelizuamb (PD-1 Antibody) as Adjuvant Therapy in High-risk Non-metastatic Nasopharyngeal Carcinoma: a Multicentre, Open-label, Randomised Phase 3 Trial

Last checked: Nov 20, 2026Latest source record: Apr 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 556 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

556

Planned (sponsor's estimate)

Start

Apr 17, 2022

Primary completion

Jun 2027

Study completion Jun 2029

Sponsor

Lead sponsor
Sun Yat-sen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Tongji Hospital; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Xiangya Hospital of Central South University; Affiliated Cancer Hospital of Guizhou Medical University; Cancer Hospital of Guangxi Medical University; First People's Hospital of Foshan; Chongqing University Cancer Hospital; Hubei Cancer Hospital; Hunan Cancer Hospital; The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School; Fifth Affiliated Hospital, Sun Yat-Sen University; Shandong Provincial Hospital
First posted
Apr 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is aimed to investigate whether additional adjuvant PD-1 antibody treatment could improve survival in high-risk nasopharyngeal carcinoma compared to metronomic capecitabine alone.

Conditions

  • Nasopharyngeal Carcinoma

Interventions

  • PD-1 antibodyDrug

    Tislelizumab:200 mg per dose, intravenous infusion over 30 minutes, every 3 weeks as a cycle for 17 cycles after concurrent chemoradiotherapy

  • CapecitabineDrug

    Capecitabine : 650 mg/m2 bid, orally, d1-21, every 3 weeks as a cycle for 17 cycles after concurrent chemoradiotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. failure-free survivalTime frame: 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.